Cancer Does Not Kill – Chemotherapy Kills

  • Chemotherapy Kills

    What they do not want you to know

    Grief and Anger statue lying o ground graveyard dark

Cancer Does Not Kill – Chemotherapy Kills

What Big-Pharma and it’s pharmaceutically trained doctors do not want you to know.

“Most cancer patients in this country die of chemotherapy. Chemotherapy does not eliminate breast, colon, or lung cancers. This fact has been documented for over a decade, yet doctors still use chemotherapy for these tumors,” – Albert Braverman MD 1991 Lancet 1991 337 p901 “Medical Oncology in the 90s.

 

Cancer is too profitable to allow a cure

This is a must-read before you consider chemotherapy. We will get right to it. Chemotherapy has one main adverse side effect—death, and it is very prevalent. Just glance below at the deadly toxic side effects. Many of the adverse life altering conditions chemo causes will be permanent.

When people die from one of the conditions on the list that was caused by chemotherapy—the death is certificate has the cause of death as that condition and not the cancer or the chemotherapy.  If it were not a deceptive world and a multi-trillion-dollar cancer industry; the cause of death would be listed as chemotherapy.

Are you aware that we all have cancer within our bodies? Our healthy immune system will fight it off multiple times throughout our lifetime, and we don’t even know it.

Our immune sytem is able to battle cancer and keep it at bay and does many times througout the years. It is when our immune system gets weak that the cancer wins the battle and begins to metastasize. Chemotherapy destroys the immune system and the body’s ablity to fight cancer; hence, the secondary cancers.

Our immune systems get weakened by a plethora of different factors which we will discuss while in more detail when we look at how to cure cancer.

We have been programmed to believe that chemo and radiation are our only option, and most people are not aware what we are discussing or aware of the hazardous potential for the adverse side effects.

Chemotherapy is a hugely toxic poison to the body. If you were to do chemo, you would be putting a toxic chemical in your body when it needs to be built up-not, and the immune system needs to be supported – not destroyed.  By enhancing the immune system, we encourage our bodies to suppress and or cure cancer.

The side effects listed say chemotherapy diminishes the immune system right on the package insert.

***Please keep in mind, as you can see below, one paper states as fact 9% of people developed serious adverse side effects. The very next line, they declare this amount as being “RARE.” So 9% Adverse Reactions = Rare. So if 9 out of 100 people die, they rarely die from the treatment.

They Consider 29% of People having side effects “LESS COMMON”

This statement below is taken directly from a study:

Chlorambucil Studies – Not all side effects are listed above; some that are rare (occurring in less than 10% of patients) are not listed here. Hence, rare = less than 10%  Read the full list of side effects  LEUKERAN® (chlorambucil) Tablets

Keep in mind; most people will do a chemotherapy regimen. Often the doctor does not give details, nor discusses these side effects or goes over the black box warnings as they should.  They will then combine and administer several of these toxic drugs at once.

For example, the CHOP regimen, which includes cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin), and prednisone, is typical.  See below the side effects for the CHOP regimen, which include; death, blindness, kidney failure, liver failure, secondary cancers, seizures, coma, anaphylaxis, heart attacks, and much much more.

Chemotherapy is 2.1% Effective towards a 5-year Survival Rate

“An investigation by the Department of Radiation Oncology, Northern Sydney Cancer Centre, Australia, into the contribution of chemotherapy to 5-year survival in 22 major adult malignancies, showed startling results: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.”
-Royal North Shore Hospital, Clinical Oncology (2005): 17.4, pg. 294.

You read that right. Overall, it is 2.1% effective in the USA. Now please read all of the deadly, toxic potential side effects and ask yourself if it is worth the risk? Keeping in mind that there is the potential for these results to be exaggerated since the manufacturers in the pharmaceutical industry do the testing themselves. We have an abundance of articles on the falsification and fraud throughout the clinical trial testing industry.

Why will they not discuss a ten-year survival rate? A twenty-year survival rate? Because chemotherapy has no positive effect on a ten-year survival rate.

They hide the fact that chemotherapy causes secondary cancers. The doctor knows this but does not sit you down and say after the chemo, which may shrink the tumor for a short time, you will have a high probability of getting another cancer, and now since we will have completely destroyed your immune system, you will then die.

The information is readily available, but your doctors will not read you this article, so we will compile the science for you to understand. We provide numerous links to the scientific documentation that chemotherapy can kill you.

Quotes from Renowned Doctors and Scientists


What the experts are saying

“We have a multi-billion dollar industry that is killing people, right and left, just for financial gain. Their idea of research is to see whether two doses of this poison is better than three doses of that poison.”

—Glen Warner, M.D. oncologist.


As a chemist trained to interpret data, it is incomprehensible to me that physicians can ignore the clear evidence that chemotherapy does much, much more harm than good.”

—Dr. Alan C. Nixon, past president of the American Chemical Society


“Success of most chemotherapy is appalling…There is no scientific evidence for its ability to extend in any appreciable way the lives of patients suffering from the most common organic cancer…chemotherapy for malignancies too advanced for surgery which accounts for 80% of all cancers is a scientific wasteland.”

—Dr. Ulrich Abel. 1990

“After analysing cancer survival statistics for several decades, Dr Hardin Jones, Professor at the University of California, concluded “…patients are as well, or better off untreated.”

Just a Few Side Effects – Many Can Be Permanent

Toxic Side Effects of Cancer Drugs that can Occur

This is only a small part of the side effects list.

Many of these side effects can be permanent and many of them can kill you or lead to death.

The list is was created by listing all side effects list directly on the package inserts of the drugs. Your doctor should go over all of this with you but they do not.

A

Abdominal Pain
Acid Indigestion
Allergic  Reactions
Alopecia – the absence of hair
Anaphylaxis – Can Cause Death
Anemia
Anxiety
Arthralgias – joint pain
Asthenia – weakness
Ataxia – lack of muscle coordination, swallowing, picking up objects etc
Azotemia – High levels of nitrogen in the blood – If the kidneys cannot remove it can cause  heart failure, liver disease or damage – Can Cause Death

B

Bone Pain
Bleeding Problems
Blood Clots – Can Cause Death
Blood Pressure Changes
Blood Test Abnormalities
Breathing Problems
Bronchitis
Bruising
Low White Blood Cell Count

C

Cancer
Cardiomyopathy – Heart muscle becomes weak, enlarged or stiff – Can Cause Permanent Damage to the Heart and Death
Cardiotoxicity  – Damage to the heart
Congestive Heart Failure – Can Cause Death

C

Cataracts
Cardiotoxicity
Cardiomyopathy
Central Neurotoxicity – Confusion, memory problems and seizures
Chemo Brain – Thinking and memory problems, cognitive impairment or dysfunction
Chest Pain
Cognitive Problems
Confusion
Conjunctivitis (Pink Eye)
Constipation
Cramping
Cystitis – Inflammation of the urinary bladder

D

Deep Vein Thrombosis (DVT) – Blood Clot deep in the body – Can Cause Death
Dehydration
Depression
Diarrhea
Difficulty Breathing
Dizziness
Dry Eye Syndrome
Dyspnea – Shortness of breath

E

Early Satiety – feeling full
Edema – water retention in cavities or tissues
Electrocardiogram (ECG/EKG) changes
Electrolyte Imbalance
Esophagitis – Inflammation of the esophagus
Eye Problems

F

Fatigue
Feeling Faint
Fertility
Fever
Flatulence
Flu-like Syndrome
Flushing

G

Gastroesophageal Reflux Disease (GERD)
Genital Pain
Granulocytopenia – Decreased granulocytes (a type of white blood cell)
Gynecomastia – Enlargement of mans breasts
Glaucoma

H

Hand-Foot Syndrome – redness swelling, pain palm of hands soles of feet
Hearing Loss
Heart Failure
Heart Palpitations
Heart Problems
Heart Rhythm Changes
Heart Damage that will be permanent
Heartburn
Hematoma – a blood clot
Hemorrhagic Cystitis – Sudden onset of hematuria and bladder pain
Hematuria – Blood in urine
Hepatotoxicity – Chemical-driven liver damage
High Blood Pressure (Hypertension)
High Liver Enzymes
Hypercalcemia (High Calcium) – Causes bone pain, abnormal heart rhythms, confusion, anxiety, high blood pressure
Hyperchloremia (High Chloride) – Kidneys control levels in the blood, can be related to your kidneys
Hyperglycemia (High Blood Sugar)
Hyperkalemia (High Potassium) – Causes tiredness, chest pain, irregular heartbeats, trouble breathing, vomiting
Hyperlipasemia (High Lipase) – Excess pancreatic enzyme
Hypophosphatemia (Low Phosphorus) – included changes in mental state, confusion, anxiety, and bone issues and more

H

Hyperlipasemia (High Lipase) – Excess pancreatic enzyme
Hypermagnesemia (High Magnesium) usually related to renal failure or poor kidney function. Causes low blood pressure, neurological impairment, vomiting, nausea. Can lead to heart problems, difficulty breathing, shock and coma.
Hypernatremia (High Sodium) – Can cause nausea, fatigue, and headache
Hyperphosphatemia (High Phosphorus) – Rare except for people with severe kidney dysfunction, the kidneys do not excrete enough phosphate.
Hyperpigmentation – Dark patches and spots on the skin
Hypersensitivity Reactions – Immune system reacts abnormally to a foreign substance
Hypertriglyceridemia (High Triglycerides)
Hyperuricemia (High Uric Acid) – Strongly associated with renal disease, cardiovascular disease, and metabolic syndrome
Hypoalbuminemia (Low Albumin) – Seen in Shock, malnutrition, and inflammation
Hypocalcemia (Low Calcium)
Hypochloremia (Low Chloride)
Hypoglycemia (Low Blood Sugar)
Hypokalemia (Low Potassium) – Symptoms include weakness, tiredness, cramping in muscles, abdominal cramping and more
Hypomagnesemia (Low Magnesium) – Symptoms are usually subtle. May cause osteoporosis,  mental problems, irregular heartbeat
Hyponatremia (Low Sodium) – Symptoms include nausea, headache, confusion, and fatigue

I

Impotence

Incoordination
Insomnia
Iron Deficiency Anemia

K

Kidney Problems

L

Bilirubin – Destruction of red blood cells
Leukopenia – Reduction of white blood cells
Low Libido
Liver Dysfunction
Loss of Libido
Low Blood Counts
Low Blood Pressure
Low Platelet Count
Low Red Blood Cell Count
Lung Problems

M

Memory Loss
Menopause
Metallic Taste
Mouth Sores
Mucositis
Muscle Pain
Myalgias
Myelosuppression
Myocarditis
Neutropenic Fever
Nephrotoxicity – Kidney Toxicity
Neutropenia – Low White Blood Count
Nose Bleeds

O

Ototoxicity – Damage to inner ear responsible for hearing and balance

p

Pericarditis – Inflammation of membrane enclosing the heart
Peripheral Neuropathy – Nerve damage
Pharyngitis
Photophobia
Photosensitivity
Pneumonia
Pneumonitis
Proteinuria – bone pain, fatigue, confusion dizziness
Pulmonary Embolus (PE) – Blood Clot
Pulmonary Fibrosis – Lung Disease
Pulmonary Toxicity – Damage to the lungs
Pancytopenia – Deficiency of cells

R

Radiation Recall – Severe skin reaction

Rapid Heart Beat
Rectal Bleeding
Restlessness
Rhinitis
Ringing Ears

S

Skin Reactions
Sleep Problems
Sore Mouth
Stomatitis
Swelling
Shock
Seizures
Shortness of Breath
Sinusitis

T, U, V, W

Thrombocytopenia –  A deficiency of platelets
Thyroid Hormone Levels
Tingling
Tinnitus
Trouble Sleeping
Urinary Tract Infection
Vaginal Bleeding
Vaginal Dryness
Vaginal Infection
Vertigo
Vomiting
Water Retention
Watery Eyes
Weakness
Weight Changes

Chemotherapy Causes Cancer to Grow and Spread

This information was “accidentally” discovered as many articles put it.

You can read the full study here that shows how chemotherapy promotes cancer growth. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

We discuss chemotherapy making cancer grow and spread in more detail. When you are finished here we suggest you read about how chemotherapy makes cancer worse. 

It is the Chemotherapy that Destroys the Body

It is estimated that in 2019 – 1,762,450 will get cancer and 606,880 of people will die from it.  We believe a large amout of them will die from chemotherapy—not cancer. We believe cancer is a big-hugely-profitable-business and the alternative cures are supressed for this reason.

Chemotherapy Causes Cancer

  • Chemotherapy and radiation weaken the immune system making it easier for second cancers to develop.
  • Chemotherapy may cause the bone marrow to make abnormal cells. This can cause cancer.
  • Radiation causes damage to healthy cells. This damage can cause cancer.
  • An ordinary time for cancers to develop is from five to nine years after completion of treatment. Many do not survive second cancer. After chemotherapy, the immune system is destroyed.
  • Part of the alternative method of curing cancer has the main focus on building the immune system and rarely has secondary cancers.

Types of chemotherapy that cause cancer

High doses of chemotherapy medicines are associated with secondary cancers in some survivors. Examples of chemotherapy that may make you more likely to have second cancer include:

  • Procarbazine
  • Mechlorethamine
  • Chlorambucil
  • BCNU (bischloroethylnitrosourea)
  • Nitrogen mustard
  • Cyclophosphamide
  • Ifosfamide
  • Epipodophyllotoxins
  • Anthracyclines

Acute Toxic

CHOP THERAPY – Side Effects

A Common Chemotherapy Regimen

The CHOP regimen consists of cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin), and prednisone.

See the side effects of each CHOP therapy drug below. It is a pervasive list. It contains adverse effects such as blindness, heart attacks, and death. The toxicity levels of these chemicals that they will put in your body are incredibly high. We obtained the symbols from the left and right from the PubMed page that explains the high levels of toxicity. They also explain how you should protect yourself from coming in contact with the urine or feces of someone on chemotherapy drugs to avoid toxic exposure. The side effects are profound. We do not believe doctors tell you the details of these side effects in detail right from the start. If they did, why would you do this?

Severe Health Hazard

Vincristine (Oncovin)

Chemical in CHOP therapy

SYMPTOMS: The following symptoms of exposure have occurred during intravenous use. Symptoms of exposure include;

  • Bone marrow depression
  • Peripheral neuropathy
  • Colicky abdominal pain
  • Constipation
  • Alopecia
  • Neuromuscular and neurological disturbances
  • Gastrointestinal upset and leucopenia
  • Impaired walking
  • Convulsions
  • Hypertension
  • Inappropriate antidiuretic hormone (ADH) secretion
  • Jaw pain
  • Paresthesias in the fingers and toes
  • Sensory impairment
  • Headache
  • Loss of deep tendon reflexes
  • Parotid gland pain
  • Optic atrophy and blindness
  • Acute uric acid nephropathy
  • Myocardial infarction
  • Ocular toxicity (ptosis, other ocular muscle paresis, and 5th and 7th nerve involvement)
  • Laryngeal nerve paralysis causing hoarseness or cough
  • Depression of the achilles tendon reflex
  • Muscle pain
  • Weakness
  • Motor weakness
  • Quadriparesis
  • Numbness and tingling of the fingers and toes
  • Malaise
  • Depression
  • Psychoses
  • Neuromyopathy
  • Peripheral neuritis
  • Aynamic ileus
  • Permanent central nervous system damage
  • Paresthesia
  • Foot drop
  • Ataxia
  • Athetosis
  • Thrombocytosis
  • Coma
  • Granulocytopenia
  • Thrombocytopenia
  • Hypoplasia of all elements of bone marrow
  • Nausea, vomiting
  • Anorexia
  • Neuritic pain and motor difficulties
  • Cranial nerve neuropathy including optic nerve neuropathy and injury to the retina; cataracts
  • Facial paralysis
  • Diplopia and corneal hypesthesia
  • Anemia
  • Polyuria
  • Dysuria
  • Tingling and numbness of the extremities
  • Abdominal obstruction
  • Ischemic cardiac toxicity and syndrome of hyponatremia
  • Sensory loss
  • Slapping gait
  • Muscle wasting
  • Generalized sensorimotor dysfunction
  • Paralytic ileus, abdominal cramps
  • Rash, oral ulceration
  • Intestinal necrosis and/or perforation
  • Urinary retention due to bladder atony cranial nerve manifestations including isolated paresis and/or paralysis of muscles controlled by cranial motor nerves
  • Pharyngeal pain
  • Bone, limb and back pain
  • Malgias
  • Renal or adrenal disease
  • Hypotension
  • Dehydration
  • Azotemia and clinical edema
  • Congenital malformation in the fetus

Acute Toxic

Doxorubicin

Chemical in Chop Therapy

Doxorubicin is Anthracyclines that is used in the therapy of several forms of lymphoma, leukemia, sarcoma, and solid organ cancers. Doxorubicin is associated with a high rate of transient serum enzyme during therapy and to rare instances of clinically apparent acute liver injury with jaundice that can be severe and even fatal.

BOXED WARNING/ WARNING: CARDIOMYOPATHY. Myocardial damage, including acute left ventricular failure can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20%

BOXED WARNING/ WARNING: SEVERE MYELOSUPPRESSION. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur.

SECONDARY MALIGNANCIES. Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride.

BOXED WARNING/ WARNING: EXTRAVASATION AND TISSUE NECROSIS. Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.

Adverse Reactions

  • Combination antineoplastic regimens can cause sinusoidal obstruction syndrome, but the role of doxorubicin, epirubicin and idarubicin in this outcome is often not clear.
  • The use of conventional or liposomal doxorubicin may cause cardiac toxicity.
  • Chronic cardiotoxicity, such as congestive heart failure or cardiomyopathy, usually occurs within 1 year after discontinuance of anthracycline therapy, is more common than acute cardiotoxicity, and is considered clinically the most important anthracycline-associated toxicity. Tachycardia, tachypnea, dilation of the heart, exercise intolerance, pulmonary and venous congestion, poor perfusion, and pleural effusion; these manifestations may respond to cardiac supportive therapy and may be self-limiting, or, alternatively, may be irreversible and unresponsive to therapy and fatal. In one retrospective review, congestive heart failure developed in 3, 7, or 21% of patients
  • Late-onset anthracycline-induced cardiotoxicity, which may be life-threatening, occurs several years or even decades after discontinuance of anthracycline therapy and it may develop after a prolonged asymptomatic interval.
  • Adverse cardiovascular effects reported in 1-10% of patients receiving pegylated liposomal doxorubicin for ovarian cancer include vasodilation, tachycardia, deep thrombophlebitis, hypotension, pallor, and cardiac arrest.
  • Ulceration and necrosis of the colon, particularly the cecum, leading to bleeding or severe and possibly fatal infection, have occurred in patients with acute myelogenous leukemia who received combined doxorubicin and cytarabine therapy.
  • Flushing
  • Shortness of breath
  • Facial edema
  • Headache
  • Chills
  • Chest pain
  • Back pain
  • Tightness of the chest and throat
  • Fever
  • Tachycardia
  • Pruritus
  • Rash
  • Cyanosis, syncope
  • Bronchospasm
  • Asthma
  • Apnea, and hypotension
  • Anaphylactoid-like reactions, sometimes life-threatening or fatal, also have been reported. Among patients receiving pegylated liposomal doxorubicin for AIDS-related Kaposi’s sarcoma, allergic reactions were reported in 1-5% of patients.
  • Seizures and coma have been reported in patients receiving doxorubicin in combination with cisplatin or vincristine.
  • Medications and emergency equipment for the treatment of allergic or anaphylactoid-like reactions should be available for immediate use in patients receiving liposomal doxorubicin
  • The use of doxorubicin or other topoisomerase II inhibitors in children is associated with increased risk of acute myelogenous leukemia and other secondary malignancies.
  • Caregivers of children receiving doxorubicin should be advised to take precautions (e.g., wearing latex gloves) to prevent contact with the patient’s urine and other body fluids for at least five days after administration of doxorubicin.

Cyclophosphamide

Chemical in Chop Therapy

Reminder: the standard definition of rare is less than 10%

Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards.

  • Second malignancies have developed in some patients treated with Cyclophosphamide
  • It may cause sterility in both sexes.
  • Ovarian fibrosis, with apparently complete loss of germ cells after prolonged Cyclophosphamide treatment in late prepubescence, has been reported.
  • Hemorrhagic cystitis may develop in patients treated with Cyclophosphamide. Rarely, this condition can be severe and even fatal. Fibrosis of the urinary bladder, sometimes extensive, also may develop with or without accompanying cystitis.
  • Anaphylactic reactions have been reported; death has also been reported in association with this event.
  • In a few instances with high doses of Cyclophosphamide, severe, and sometimes fatal, congestive heart failure has occurred after the first Cyclophosphamide dose. Histopathologic examination has primarily shown hemorrhagic myocarditis. Hemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis.
  • Pericarditis has been reported independent of any hemopericardium.

Treatment with Cyclophosphamide may cause significant suppression of immune responses. Serious, sometimes fatal, infections may develop in severely immunosuppressed patients.

PRECAUTIONS:

While you are being treated with cyclophosphamide, and after you stop treatment with it, do not have any immunizations (vaccines) without your doctor’s approval. Cyclophosphamide may lower your body’s resistance and the vaccine may not work as well or you might get the infection the vaccine is meant to prevent. In addition, you should not be around other persons living in your household who receive live virus vaccines because there is a chance they could pass the virus on to you. Some examples of live vaccines include measles, mumps, influenza (nasal flu vaccine), poliovirus (oral form), rotavirus, and rubella. Do not get close to them and do not stay in the same room with them for very long. If you have questions about this, talk to your doctor.

Cyclophosphamide can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low.

  • Cyclophosphamide has been shown to increase the risk of secondary malignancies such as leukemia and urothelial cell carcinoma
  • Leukopenia occurs in patients treated with Cyclophosphamide
  • Fast heartbeat
  • Joint pain
  • Shortness of breath
  • Swelling of the feet or lower legs
  • Unusual tiredness or weakness
  • Less common
  • Black, tarry stools
  • Pinpoint red spots on the skin
  • Abnormal bleeding or bruising
  • Rare
  • Frequent urination
  • Redness, swelling, or pain at the injection site
  • Sores in the mouth and on the lips
  • Sudden shortness of breath
  • Unusual thirst
  • Yellow eyes or skin

The CHOP Chemotherapy Regimen

  • Cardiovascular: Acute cardiotoxicity: Atrioventricular block, bradycardia, bundle branch block, ECG abnormality, extrasystoles (atrial or ventricular), nonspecific ST or T wave changes on ECG, sinus tachycardia, supraventricular tachycardia, tachyarrhythmia, ventricular tachycardiaDelayed cardiotoxicity: Cardiac failure (manifestations include ascites, cardiomegaly, dyspnea, edema, gallop rhythm, hepatomegaly, oliguria, pleural. Cardiomyopathy with incidences from 1% to 20%.
  • Hematologic & oncologic: Leukopenia (≤75%; nadir: 10 to 14 days; recovery: by day 21), neutropenia (≤75%; nadir: 10 to 14 days; recovery: by day 21), anemia, thrombocytopeniaeffusion, pulmonary edema, tachycardia), decreased left ventricular ejection fraction, myocarditis, pericarditis.
  • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin. It usually occurs within one to three years.  May cause tumor lysis syndrome (dying cells release large amounts of potassium, phosphate, and uric acid into the blood. This can cause heart or kidney problems and lead to kidney failure. can cause seizures) TLS can become life-threatening if is not managed or treated Can also cause hyperuricemia (gout)
  • Myelosuppression: Severe myelosuppression, resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death, may occur.

Side Effects of Common Chemotherapy Drugs

MATULANE® Procarbazine –  Adverse Side Effects

Leukopenia -A condition of a  reduced number of white blood cells. This increases the risk of infections. It destroys the immune system.

  • fever higher than 100.5˚F (38˚C)
  • chills
  • sweating

Anemia – When your blood lacks enough healthy red blood cells or hemoglobin.

  • Fatigue and loss of energy
  • Unusually rapid heart beat
  • Shortness of breath and headache
  • Difficulty concentrating
  • Dizziness
  • Pale skin
  • Leg cramps
  • Insomnia

Thrombocytopenia  (A lower platelet count can cause bleeding problems) have been reported to occur frequently.

Pancytopenia – 

  • Feeling tired, weak, dizzy, or short of breath
  • Frequent fevers or infections
  • Pale skin or purple or red dots on the skin
  • Bleeding from the gums or nose, blood in bowel movements or urine, or heavy bleeding from a cut

Eosinophilia

Can cause hypereosinophilic syndrome – damage to the heart leading to cardiac failure. Causes shortness of breath and swollen ankles; can cause the development of rashes on the skin. Can also cause enlargement of the spleen and liver.

hemolytic anemia

  • Dizziness or trouble thinking clearly
  • Feeling tired and weak
  • Shortness of breath upon exertion
  • A faster heartbeat than a usual heartbeat.
  • Pale or yellow skin
  • Dark urine

Bleeding problems including:

Petechiae – When capillaries bleed, leaking blood into the skin.

Purpura -also called blood spots or skin hemorrhages epistaxis

Hematuria –

  • Fever
  • Nausea and vomiting
  • Pain or bruising on your lower back or sides
  • Pain when you urinate
  • More urination than usual, or the need to urinate right away

Hemoptysis

  • Spitting of blood that originated in the lungs or bronchial tubes.

Peripheral neuropathy with paresthesia (pricking, chilling, burning, or numb sensation) of the extremities and depressed deep tendon reflexes were reported to occur in 17% of patients.  May become permanent

Ataxia – May become permanent – slurred speech, stumbling, falling, and incoordination. All are related to degeneration of the part of the brain responsible for coordination, called the cerebellum.

TMUSTARGEN®  Cancer-Causing Chemotherapy Drug

Label Warning:

This drug is HIGHLY TOXIC and both powder and solution must be handled and administered with care. Inhalation of dust or vapors and contact with skin or mucous membranes, especially those of the eyes, must be avoided. Avoid exposure during pregnancy. Due to the toxic properties of mechlorethamine (e.g., corrosivity, carcinogenicity, mutagenicity, teratogenicity), special handling procedures should be reviewed prior to handling and followed diligently.

  • Hyperheparinemia
  • Vascular Accidents
  • Anorexia
  • Thrombocytopenia
  • Maculopapular skin eruption
  • Erythema multiforme
  • Herpes Zoster
  • Oligomenorrhea –  Infrequent menstrual periods
  • Temporary or permanent amenorrhea. – No menstrual periods
  • Impaired spermatogenesis, azoospermia, and total germinal aplasia. (Infertility may be reversed several years after stopping drug)
  • Nausea/vomiting (may be severe)
  • Anaphylaxis
  •  Hemolytic anemia associated with such diseases as the lymphomas and chronic lymphocytic leukemia
  • Chromosomal abnormalities
  • Confusion
  • Drowsiness
  • Weakness
  • Mouth sores
  • Spinning sensation or dizziness (vertigo)
  • Temporary hair loss
  • Rash
  • Ringing in the ears or decreased ability to hear

As nitrogen mustard therapy may contribute  to Amyloidosis; a serious health problem that can lead to life-threatening organ failure. Amyloidosis frequently involves the heart and kidneys. It is a rare disease but it is induced by this drug as a side effect. It is an extremely serious condition caused by this toxic chemotherapy drug.

  • An enlarged heart (cardiomegaly)
  • Irregular heartbeat (arrhythmias)
  • Abnormalities of the heart seen on electrocardiograms
  • Congestive heart failure is the most common cardiac complication of amyloidosis.

Amyloidosis can affect your kidneys, heart, liver, intestines, and nerves.

Mustargen has been reported to have immunosuppressive activity. It may predispose the patient to bacterial, viral or fungal infection. It destroys your bodies natural ability to fight off cancer.

Mustargen may be associated with an increased incidence of a second malignant tumor. The cancer drug causes cancer.

Severe thrombocytopenia may lead to bleeding from the gums and gastrointestinal tract, petechiae, and small subcutaneous hemorrhages.

Persistent pancytopenia (low counts for all three types of blood cells: red blood cells, white blood cells, and platelets.) have been reported.

  • confusion – loss of consciousness – seizures – shortness of breath – significant blood loss.

Rarely, hemolytic anemia associated with such diseases as the lymphomas and chronic lymphocytic leukemia may be precipitated by treatment with alkylating agents including Mustargen. This drug causes cancer

LEUKERAN® 3 (chlorambucil)

These are less common side effects (occurring in 10-29%) for patients receiving chlorambucil:

  • Nausea and vomiting.
  • Skin rash (a severe skin reaction is a rare but serious side effect of chlorambucil.  Promptly report any skin rashes or reactions to your health care provider).
  • Increases in blood tests measuring liver function.  These return to normal once treatment is discontinued. (see liver problems).

So What Does “RARE” Mean? OR “RELATIVELY RARE”?

As we stated, it appears to be 10% or less is rare.

The following side effects are rare for patients receiving chlorambucil, discuss any concerns regarding these with your health care professional:

  • Increased risk of developing a secondary malignancy such as acute leukemia, with long-term use of this drug.
  • Your fertility, meaning your ability to conceive or father a child, may be affected by chlorambucil.
  • Pulmonary toxicity (damage to the lungs) has occurred in higher, long term (> 6 months) doses of chlorambucil.  This is a relatively rare event.

The most common side effect is bone marrow suppression, anemia, leukopenia, neutropenia, thrombocytopenia, or pancytopenia. (See Definitions Above) Although bone marrow suppression frequently occurs, it is usually reversible if the chlorambucil is withdrawn early enough.

However, irreversible bone marrow failure has been reported.

Alveolitis and lung fibrosis following therapy with chlorambucil

A condition of inadequate oxygenation of the blood as a result of the failure of oxygen to pass across the membranes between the lung ALVEOLI and the blood capillaries.

Fatal intraalveolar and interstitial lung fibrosis in chlorambucil-treated chronic lymphocytic leukemia.

Leukeran® Side Effects Continued

Carcinogenesis, Mutagenesis, Impairment of Fertility

Leukeran (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility (see WARNINGS and PRECAUTIONS).

Convulsions, infertility, leukemia, and secondary malignancies have been observed when chlorambucil was employed in the therapy of malignant and non-malignant diseases. Erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome – can cause death – SJS Complications can include hepatitis, nephritis, gastrointestinal bleeding, pneumonia, arthritis, arthralgia, fever, and myalgia. Some say your skin burns from the inside out.

Tremors, muscular twitching, myoclonia, confusion, agitation, ataxia, flaccid paresis, and hallucinations, focal and/or generalized seizures have been reported to occur in both children and adults. Chromatid or chromosome damage and non-reversable and reversable sterility.

The quantitation of the risk of chlorambucil-induction of leukemia or carcinoma in humans is not possible. So with all the science they tell you they can not give you a clue how many people get cancer from this drug?

Chlorambucil does not prolong survival in patients with stage A indolent chronic lymphocytic leukemia (CLL)

Since deferring therapy until the disease progresses to stage B or C does not compromise survival, treatment of indolent CLL is unnecessary.

Not Studied:

The impact of renal impairment on chlorambucil elimination has not been formally studied.

The safety and effectiveness in pediatric patients have not been established.

Chlorambucil can cause fetal harm when administered to a pregnant woman. Unilateral renal agenesis (lack of developement)has been observed in 2 offspring whose mothers received chlorambucil during the first trimester.


Randomized clinical trials that compared chlorambucil to different regimens, for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not support an overall survival (OS) benefit.


Bischloroethylnitrosourea (BCNU) Toxic Chemotherapy Drug

Here is what your cancer drug is doing.

Delayed pulmonary toxicity syndrome, characterized by interstitial pneumonia and pulmonary fibrosis, is common following high-dose bischloroethylnitrosourea (BCNU) (carmustine, [1,3-bis (2-chloroethyl)-1-nitrosourea]) containing chemotherapeutic regimens. Depending upon the treatment protocol, it may develop in over 70% of patients.

Ten patients developed pulmonary fibrosis after bischloroethylnitrosourea (BCNU) therapy for malignancy. This was lethal in seven patients, four of whom had no evidence of tumor at autopsy.


There is a slight risk of developing a blood cancer such as leukemia after taking carmustine. Severe side effects CTCAE III/IV were observed in 9 % of patients including severe hematotoxicity, thromboembolism, intracranial hemorrhage and injection site reaction requiring surgical intervention.

One patient presented with a clinically apparent pulmonary fibrosis CTCAE IV requiring temporary mechanical ventilation.

Conclusion

In this study, BCNU was rarely associated with severe side effects. SO 9% IS CONSIDERED RARE.


Cyclophosphamide – Toxic Chemotherapy Drug

Here is what your cancer drug is doing.

Infections:

Treatment with Cyclophosphamide may cause significant suppression of immune responses. Severe, sometimes fatal, infections may develop in severely immunosuppressed patients. Your body will no longer be able to fight cancer as it usually does.

Warnings

Carcinogenesis, Mutagenesis, and Impairment of Fertility:

Second malignancies have developed in patients after use of Cyclophosphamide. It may cause sterility in both men and women. Hemorrhagic cystitis may develop after use of Cyclophosphamide. This condition can be severe and even fatal. The incidence and risk of serious, life-threatening bladder hemorrhage from cyclophosphamide therapy is increased by prior or concurrent pelvic irradiation.

Anthracyclines

Chronic toxicity of anthracyclines occurs weeks or months after administration.

Instead of continuing each chemotherapy side effect listed on the package inserts we have compiled a list of every side effect on this page so far.

List of Side Effects listed from this Article Alone

Abdominal obstruction
Hemolytic anemia associated with such diseases as the lymphomas and chronic lymphocytic leukemia
A faster heartbeat than a usual heartbeat.
Abnormal bleeding or bruising
Abnormalities of the heart seen on electrocardiograms
Acute uric acid nephropathy
Adverse cardiovascular effects reported in 1-10% of patients receiving pegylated liposomal doxorubicin for ovarian cancer include vasodilation, tachycardia, deep thrombophlebitis, hypotension, pallor, and cardiac arrest.
Alopecia
Amyloidosis can affect your kidneys, heart, liver, intestines, and nerves.
An enlarged heart (cardiomegaly)
Anaphylactic reactions have been reported; death has also been reported in association with this event.
Anemia
Anorexia
Apnea
As nitrogen mustard therapy may contribute  to Amyloidosis; a serious health problem that can lead to life-threatening organ failure. Amyloidosis frequently involves the heart and kidneys. It is a rare disease but it is induced by this drug as a side effect. It is an extremely serious condition caused by this toxic chemotherapy drug.
Asthma
Ataxia – May become permanent – slurred speech, stumbling, falling, and incoordination. All are related to degeneration of the part of the brain responsible for coordination, called the cerebellum.
Athetosis
Aynamic ileus
Azotemia
Back pain
Black, tarry stools
Bleeding from the gums or nose, blood in bowel movements or urine, or heavy bleeding from a cut
Bleeding problems including:
Bone marrow depression
Bone, limb and back pain
BOXED WARNING/ WARNING: CARDIOMYOPATHY. Myocardial damage, including acute left ventricular failure can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20%
BOXED WARNING/ WARNING: SEVERE MYELOSUPPRESSION. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur.
Bronchospasm
Can cause hypereosinophilic syndrome – damage to the heart leading to cardiac failure. Causes shortness of breath and swollen ankles; can cause the development of rashes on the skin. Can also cause enlargement of the spleen and liver.
Caregivers of children receiving doxorubicin should be advised to take precautions (e.g., wearing latex gloves) to prevent contact with the patient’s urine and other body fluids for at least five days after administration of doxorubicin.
Chest pain
Chills
Chromosomal abnormalities
Chronic cardiotoxicity, such as congestive heart failure or cardiomyopathy, usually occurs within 1 year after discontinuance of anthracycline therapy, is more common than acute cardiotoxicity, and is considered clinically the most important anthracycline-associated toxicity. Tachycardia, tachypnea, dilation of the heart, exercise intolerance, pulmonary and venous congestion, poor perfusion, and pleural effusion; these manifestations may respond to cardiac supportive therapy and may be self-limiting, or, alternatively, may be irreversible and unresponsive to therapy and fatal. In one retrospective review, congestive heart failure developed in 3, 7, or 21% of patients
Colicky abdominal pain
Coma
Combination antineoplastic regimens can cause sinusoidal obstruction syndrome, but the role of doxorubicin, epirubicin and idarubicin in this outcome is often not clear.
Confusion
Congenital malformation in the fetus
Congestive heart failure is the most common cardiac complication of amyloidosis.
Constipation
Convulsions
Cranial nerve neuropathy including optic nerve neuropathy and injury to the retina; cataracts
Cyanosis, syncope
Cyclophosphamide has been shown to increase the risk of secondary malignancies such as leukemia and urothelial cell carcinoma
Dark urine
Dehydration
Depression
Depression of the achilles tendon reflex
Difficulty concentrating
Diplopia and corneal hypesthesia
Dizziness or trouble thinking clearly
Drowsiness
Dysuria
Eosinophilia
Erythema multiforme
Facial edema
Facial paralysis
Fast heartbeat
Fatigue and loss of energy
Feeling tired and weak
Feeling tired, weak, dizzy, or short of breath

Fever higher than 100.5˚F (38˚C)
Flushing
Foot drop
Frequent fevers or infections
Frequent urination
Gastrointestinal upset and leucopenia
Generalized sensorimotor dysfunction
Granulocytopenia
Headache
Hematuria
Hemolytic anemia
Hemoptysis
Hemorrhagic cystitis may develop in patients treated with Cyclophosphamide. Rarely, this condition can be severe and even fatal. Fibrosis of the urinary bladder, sometimes extensive, also may develop with or without accompanying cystitis.
Herpes Zoster
Hyperheparinemia
Hypertension
Hypoplasia of all elements of bone marrow
Hypotension
Impaired spermatogenesis, azoospermia, and total germinal aplasia. (Infertility may be reversed several years after stopping drug)
Impaired walking
In a few instances with high doses of Cyclophosphamide, severe, and sometimes fatal, congestive heart failure has occurred after the first Cyclophosphamide dose. Histopathologic examination has primarily shown hemorrhagic myocarditis. Hemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis.
Inappropriate antidiuretic hormone (ADH) secretion
Insomnia
Intestinal necrosis and/or perforation
Irregular heartbeat (arrhythmias)
Ischemic cardiac toxicity and syndrome of hyponatremia
It may cause sterility in both sexes.
Jaw pain
Joint pain
Laryngeal nerve paralysis causing hoarseness or cough
Late-onset anthracycline-induced cardiotoxicity, which may be life-threatening, occurs several years or even decades after discontinuance of anthracycline therapy and it may develop after a prolonged asymptomatic interval.
Leg cramps
Leukopenia occurs in patients treated with Cyclophosphamide
Loss of deep tendon reflexes
Maculopapular skin eruption
Malaise
Malgias
More urination than usual, or the need to urinate right away
Motor weakness
Mouth sores
Muscle pain
Muscle wasting
Mustargen has been reported to have immunosuppressive activity. It may predispose the patient to bacterial, viral or fungal infection. It destroys your bodies natural ability to fight off cancer.
Mustargen may be associated with an increased incidence of a second malignant tumor. The cancer drug causes cancer.
Myocardial infarction
Nausea/vomiting (may be severe)
Neuritic pain and motor difficulties
Neuromuscular and neurological disturbances
Neuromyopathy
Numbness and tingling of the fingers and toes
Ocular toxicity (ptosis, other ocular muscle paresis, and 5th and 7th nerve involvement)
Oligomenorrhea –  Infrequent menstrual periods
Optic atrophy and blindness
Ovarian fibrosis with apparently complete loss of germ cells after prolonged Cyclophosphamide treatment in late prepubescence has been reported.
Pain or bruising on your lower back or sides
Pain when you urinate
Pale or yellow skin
Pale skin
Pale skin or purple or red dots on the skin
Pancytopenia
Paralytic ileus, abdominal cramps
Paresthesia
Paresthesias in the fingers and toes
Parotid gland pain
Pericarditis has been reported independent of any hemopericardium.
Peripheral neuritis
Peripheral neuropathy
Peripheral neuropathy with paresthesia (pricking, chilling, burning, or numb sensation) of the extremities and depressed deep tendon reflexes were reported to occur in 17% of patients.  May become permanent
Permanent central nervous system damage
Persistent pancytopenia (low counts for all three types of blood cells: red blood cells, white blood cells, and platelets.) have been reported.
Petechiae – When capillaries bleed, leaking blood into the skin.
Pharyngeal pain
Pinpoint red spots on the skin
Polyuria
Pruritus
Psychoses
Purpura -also called blood spots or skin hemorrhages epistaxis
Quadriparesis
Rarely, hemolytic anemia associated with such diseases as the lymphomas and chronic lymphocytic leukemia may be precipitated by treatment with alkylating agents including Mustargen. This drug causes cancer
Rash
Rash, oral ulceration
Redness, swelling, or pain at the injection site
Renal or adrenal disease
Ringing in the ears or decreased ability to hear
Second malignancies have developed in some patients treated with Cyclophosphamide
SECONDARY MALIGNANCIES. Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride
Seizures and coma have been reported in patients receiving doxorubicin in combination with cisplatin or vincristine.
Sensory impairment
Sensory loss
Severe thrombocytopenia may lead to bleeding from the gums and gastrointestinal tract, petechiae, and small subcutaneous hemorrhages.
Shortness of breath
Shortness of breath upon exertion
Slapping gait
Sores in the mouth and on the lips
Spinning sensation or dizziness (vertigo)
Spitting of blood that originated in the lungs or bronchial tubes.
Sudden shortness of breath
Sweating
Swelling of the feet or lower legs
Tachycardia
Temporary hair loss
Temporary or permanent amenorrhea. – No menstrual periods
The use of conventional or liposomal doxorubicin may cause cardiac toxicity.
The use of doxorubicin (Chemo drug) or other topoisomerase II inhibitors in children is associated with increased risk of acute myelogenous leukemia and other secondary malignancies.
Thrombocytopenia
Thrombocytopenia  (A lower platelet count can cause bleeding problems) have been reported to occur frequently.
Thrombocytosis
Tightness of the chest and throat
Tightness of the chest and throat
Tightness of the chest and throat
Tingling and numbness of the extremities
Ulceration and necrosis of the colon, particularly the cecum, leading to bleeding or severe and possibly fatal infection, have occurred in patients with acute myelogenous leukemia who received combined doxorubicin and cytarabine therapy.
Unusual thirst
Unusual tiredness or weakness
Unusually rapid heart beat
Urinary retention due to bladder atony cranial nerve manifestations including isolated paresis and/or paralysis of muscles controlled by cranial motor nerves
Vascular Accidents
Weakness
Yellow eyes or skin